Am BioPark 13
93053 Regensburg, de
+49 (941) 6309197-85
Lophius Biosciences Receives Public Grant for the Development of an Advanced Diagnostic Tuberculosis Test
Lophius Biosciences GmbH today announced that it has been awarded a public grant funding of 0.65 MEUR from the German Federal Ministry of Education and Research to develop a blood based test for the rapid and efficient diagnosis of tuberculosis
There are more than 10 million new TB incidences per year and 1.4 million associated deaths. This places TB among the top 10 causes of death worldwide, despite most cases being curable. In total, 1.7 billion people are estimated to be latently infected globally. Although over 95% of TB deaths occur in low- and middle income countries, TB incident rates are climbing in industrialized countries in recent years. This is largely due to increasing mobility and the rise of multi-resistant bacterial strains. Currently, reliable diagnosis of active TB is complex, laborious and thus time-consuming by combining a number of different diagnostic methods like X-ray, sputum microscopy, sputum culture, sputum PCR and IFN-γ release assays.
Based on its proprietary RTT platform Lophius aims to develop a test with the potential to significantly simplify and accelerate the current workflow of TB diagnosis by enabling an efficient differentiation of patients with active TB from latently infected and healthy individuals with a single, easy to use blood-based test. “The assignment of this grant in a competitive process confirms the high unmet needs in the TB market and underlines the potential of our technology. It will help us to broaden and accelerate our development activities”, commented Bernd Merkl, CEO & Managing Director of Lophius Biosciences GmbH.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.